Analysts Set Amedisys Inc (NASDAQ:AMED) Price Target at $191.53

Amedisys Inc (NASDAQ:AMED) has earned a consensus recommendation of “Buy” from the seventeen brokerages that are currently covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $191.53.

A number of equities analysts have weighed in on the company. Zacks Investment Research raised Amedisys from a “hold” rating to a “buy” rating and set a $193.00 price target on the stock in a research report on Friday, May 1st. Raymond James reduced their price objective on Amedisys from $225.00 to $210.00 and set an “outperform” rating for the company in a report on Monday, May 11th. BidaskClub cut Amedisys from a “buy” rating to a “hold” rating in a report on Saturday, June 6th. Royal Bank of Canada restated a “buy” rating and set a $218.00 price objective on shares of Amedisys in a report on Sunday, May 10th. Finally, Oppenheimer restated a “buy” rating and set a $215.00 price objective on shares of Amedisys in a report on Monday, April 27th.

In related news, insider David L. Kemmerly sold 23,437 shares of the firm’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $175.32, for a total value of $4,108,974.84. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Sharon Brunecz sold 2,185 shares of the stock in a transaction dated Friday, June 19th. The shares were sold at an average price of $196.00, for a total transaction of $428,260.00. Following the completion of the sale, the insider now owns 23,327 shares of the company’s stock, valued at approximately $4,572,092. The disclosure for this sale can be found here. Insiders sold 39,331 shares of company stock valued at $6,964,933 over the last 90 days. 2.80% of the stock is currently owned by company insiders.

Hedge funds have recently modified their holdings of the company. Smithfield Trust Co. purchased a new stake in shares of Amedisys during the 1st quarter worth approximately $27,000. Meeder Asset Management Inc. purchased a new stake in shares of Amedisys during the 4th quarter worth approximately $36,000. Sunbelt Securities Inc. purchased a new stake in shares of Amedisys during the 4th quarter worth approximately $9,222,000. Quadrant Capital Group LLC purchased a new position in Amedisys in the 4th quarter valued at approximately $40,000. Finally, Point72 Hong Kong Ltd purchased a new position in Amedisys in the 4th quarter valued at approximately $53,000. Institutional investors own 88.21% of the company’s stock.

AMED stock traded up $2.87 during midday trading on Friday, reaching $200.34. 1,366 shares of the company’s stock traded hands, compared to its average volume of 611,226. The company has a 50-day simple moving average of $185.88 and a two-hundred day simple moving average of $180.19. Amedisys has a 1-year low of $115.41 and a 1-year high of $218.44. The company has a market cap of $6.66 billion, a price-to-earnings ratio of 51.42, a PEG ratio of 3.22 and a beta of 0.88. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.64.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Wednesday, May 6th. The health services provider reported $1.05 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.97 by $0.08. Amedisys had a return on equity of 23.09% and a net margin of 6.43%. The firm had revenue of $491.70 million for the quarter, compared to the consensus estimate of $507.45 million. During the same quarter last year, the business posted $1.11 EPS. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. Equities research analysts forecast that Amedisys will post 4.58 EPS for the current year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Recommended Story: What is the QQQ ETF?

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.